Modification of plasma lipoproteins by group IIA phospholipase A2: Possible implications for atherogenesis

Trends in Cardiovascular Medicine

Volumn 9, Issue 8, 1999, Pages 232-238

  Sartipy, Peter ^a   Hurt Camejo, Eva ^a  

^a SAHLGRENSKA UNIVERSITY HOSPITAL   (Sweden)

Author keywords

[No Author keywords available]

Indexed keywords

LIPOPROTEIN; PHOSPHOLIPASE A2;

ATHEROGENESIS; ATHEROSCLEROSIS; DISEASE COURSE; HUMAN; LIPOLYSIS; LIPOPROTEIN BLOOD LEVEL; PHYSICAL CHEMISTRY; PRIORITY JOURNAL; REVIEW;

ANIMALS; ARTERIES; ARTERIOSCLEROSIS; CHEMISTRY, PHYSICAL; DISEASE MODELS, ANIMAL; HUMANS; HYDROLYSIS; LIPOPROTEINS; PHOSPHOLIPASES A;

EID: 0033292940     PISSN: 10501738     EISSN: None     Source Type: Journal    
DOI: 10.1016/S1050-1738(00)00030-X     Document Type: Review

References (68)

1. Enzymatic probes of lipoprotein structure. Hydrolysis of human serum low density lipoprotein-2 by phospholipase A2
2. Phospholipase A2-modified LDL is taken up at enhanced rate by macrophages
3. Expression of secretory group II phospholipase A2 by CD1a positive cells-in human atherosclerotic plaques
4. Association of apo B lipoproteins with arterial proteoglycans: Pathological significance and molecular basis
5. Evidence for lipid-dependent structural changes in specific domains of apolipoprotein B100
6. A modified form of low-density lipoprotein with increased electronegative charge is present in rheumatoid arthritis synovial fluid
7. Secretory non-pancreatic phospholipase A2: Influence on lipoprotein metabolism
8. The growing phospholipase A2 superfamily of signal transduction enzymes
9. Minimal oxidation and storage of low density lipoproteins result in an increased susceptibility to phospholipid hydrolysis by phospholipase A2
10. Expression of phospholipase A2 isoforms in human normal and atherosclerotic arterial wall
11. Effect of phospholipase A2 digestion on the conformation and lysine/fibrinogen binding properties of human lipoprotein[a]
12. Platelet-activating factor and oxidized LDL induce immune activation by a common mechanism
13. Interfacial enzymology of glycerolipid hydrolases: Lessons from secreted phospholipases A2
14. Alterations in the physiochemical characteristics of low and high density lipoproteins after lipolysis with phospholipase A2. A spin-label study
15. Expression of human group II PLA2 in transgenic mice results in epidermal hyperplasia in the absence of inflammatory infiltrate
16. Lipolytic modification of LDL by phospholipase A2 induces particle aggregation in the absence and fusion in the presence of heparin
17. Phospholipase A2 modification enhances lipoprotein(a) binding to the subendothelial matrix
18. Enzymatic and chemical modifications of lipoprotein(a) selectively alter its lysine-binding functions
19. Induction of IL-4 by platelet-activating factor
20. Localization of nonpancreatic secretory phospholipase A2 in normal and atherosclerotic arteries. Activity of the isolated enzyme on low-density lipoproteins
21. Potential involvement of type II phospholipase A2 in atherosclerosis
22. Cellular consequences of the association of apoB lipoproteins with proteoglycans. Potential contribution to atherogenesis
23. Role of group II secretory phospholipase A2 in atherosclerosis: 1. Increased atherogenesis and altered lipoproteins in transgenic mice expressing group IIa phospholipase A2
24. A novel endothelial-derived lipase that modulates HDL metabolism
25. A natural disruption of the secretory group II phospholipase A2 gene in inbred mouse strains
26. Lipolysis of LDL with phospholipase A2 alters the expression of selected apoB-100 epitopes and the interaction of LDL with cells
27. Induction by lysophosphatidylcholine, a major phospholipid component of atherogenic lipoproteins, of human coronary artery smooth muscle cell migration
28. Structure and properties of a human non-pancreatic phospholipase A2
29. Circulating levels of secretory type II phospholipase A(2) predict coronary events in patients with coronary artery disease
30. Enzymatic modification of plasma low density lipoproteins in rabbits: A potential treatment for hypercholesterolemia
31. Sera containing elevated nonesterified fatty acids from patients with angiographically documented coronary atherosclerosis cause marked lipid accumulation in cultured human arterial smooth muscle-derived cells
32. Role of group II secretory phospholipase A2 in atherosclerosis: 2. Potential involvement of biologically active oxidized phospholipids
33. Surface properties of native human plasma lipoproteins and lipoprotein models
34. Changes in epitope exposition of apolipoprotein A-I on the surface of high density lipoproteins after phospholipase A2 treatment
35. Secretory group II phospholipase A2 in human atherosclerotic plaques
36. Exposure of macrophages to PLA2-modified lipoproteins leads to cellular lipid accumulations
37. Measurement of platelet-activating factor in a canine model of coronary thrombosis and in endarterectomy samples from patients with advanced coronary artery disease
38. Enhanced binding of phospholipase-A2-modified low density lipoprotein by human adipocytes
39. Secretory phospholipase A2 and lipoprotein lipase enhance 15-lipoxygenase-induced enzymic and nonenzymic lipid peroxidation in low-density lipoproteins
40. Serum phospholipase A2 in inflammatory diseases
41. Expression of human group II phospholipase A2 in transgenic mice
42. Fatty acids modulate the composition of extracellular matrix in cultured human arterial smooth muscle cells by altering the expression of genes for proteoglycan core proteins
43. Possible functional interactions of apolipoprotein B-100 segments that associate with cell proteoglycans and the ApoB/E receptor
44. Sphingomyelinase induces aggregation and fusion, but phospholipase A2 only aggregation, of low density lipoprotein (LDL) particles. Two distinct mechanisms leading to increased binding strength of LDL to human aortic proteoglycans
45. Phospholipase A2 in juvenile rheumatoid arthritis: Correlation to disease type and activity
46. Ultrastructural localization of secretory type II phospholipase A2 in atherosclerotic and nonatherosclerotic regions of human arteries
47. Atherosclerosis - An inflammatory disease
48. Remodelling of high density lipoproteins by plasma factors
49. Lysophosphatidylcholine upregulates CD40 ligand expression in newly activated human CD4+ T cells
50. Phospholipase A2 type II binds to extracellular matrix biglycan: Modulation of its activity on LDL by colocalization in glycosaminoglycan matrixes
51. Phospholipase A(2) modification of low density lipoproteins forms small high density particles with increased affinity for proteoglycans and glycosaminoglycans
52. Binding of human phospholipase A2 type II to proteoglycans. Differential effect of glycosaminoglycans on enzyme activity
53. The atherogenic lipoprotein phenotype and vascular endothelial dysfunction
54. Analysis of secretory group II phospholipase A2 expression in human aortic tissue in dependence on the degree of atherosclerosis
55. Secretory sphingomyelinase, a product of the acid sphingomyelinase gene, can hydrolyze atherogenic lipoproteins at neutral pH. Implications for atherosclerotic lesion development
56. apoB-100 has a pentapartite structure composed of three amphipathic alpha-helical domains alternating with two amphipathic beta-strand domains. Detection by the computer program LOCATE
57. Cloning and recombinant expression of phospholipase A2 present in rheumatoid arthritic synovial fluid
58. Lysophosphatidic acid mediates the rapid activation of platelets and endothelial cells by mildly oxidized low density lipoprotein and accumulates in human atherosclerotic lesions
59. Relationship between low-density lipoprotein in aortic intima and serum-lipid levels
60. Distribution of plasma proteins across the human aortic wall - Barrier functions of endothelium and internal elastic lamina
61. Evidence that phospholipid oxidation products and/or platelet-activating factor play an important role in early atherogenesis: In vitro and in vivo inhibition by WEB 2086
62. Extracellular phospholipase A2 expression and inflammation: The relationship with associated disease states
63. Conformational changes in oxidized phospholipids and their preferential hydrolysis by phospholipase A2: A monolayer study
64. The response-to-retention hypothesis of atherogenesis reinforced
65. Decreased serum cholesterol level after snake bite (Vipera palaestinae) as a marker of severity of envenomation
66. Presence of foam cells containing oxidised low density lipoprotein in the synovial membrane from patients with rheumatoid arthritis
67. The mortality of rheumatoid arthritis
68. Lysophosphatidylcholine is involved in the antigenicity of oxidized LDL